

Prosthetic joint infections - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P498AF90CDAEN.html>

Date: June 2020

Pages: 66

Price: US\$ 2,000.00 (Single User License)

ID: P498AF90CDAEN

Abstracts

Prosthetic joint infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Pipeline Review, H1 2020, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.

Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively. Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying

and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Prosthetic Joint infections - Overview
- Prosthetic Joint infections - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Prosthetic Joint infections - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Prosthetic Joint infections - Companies Involved in Therapeutics Development
 - Armata Pharmaceuticals Inc
 - Arrevus Inc
 - ContraFect Corp
 - Lumobiotics GmbH
 - Peptilogics Inc
 - Sonoran Biosciences Inc
 - Telephus Medical LLC
 - TenNor Therapeutics Ltd
- Prosthetic Joint infections - Drug Profiles
 - (tobramycin + vancomycin SR) - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - APSA-01 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - APSA-02 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - CF-296 - Drug Profile
 - Product Description
 - Mechanism Of Action

R&D Progress

exebacase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fusidic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLG-0206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Oncology and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNP-2092 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPH-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prosthetic Joint infections - Dormant Projects

Prosthetic Joint infections - Discontinued Products

Prosthetic Joint infections - Product Development Milestones

Featured News & Press Releases

Feb 25, 2020: Peptilogs announces CARB-X funding to accelerate development of first-in-class antibiotics to address the global threat of multi-drug resistant bacteria

Jan 20, 2020: TenNor Therapeutics received FDA orphan drug designation

Jan 13, 2020: ContraFect partners with leading orthopedic center in Europe to provide compassionate use of exebacase to patients with chronic staphylococcal prosthetic joint infections

Oct 15, 2018: Peptilogs receives regulatory approval to initiate first-in-human safety study for therapeutic peptide PLG0206

Aug 24, 2018: Peptilogs completes successful pre-IND meeting with the Food and Drug Administration for PLG0206 in Prosthetic Joint Infections

Jun 02, 2018: Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection

Oct 29, 2013: Cempra Receives U.S. Orphan Drug Designation for Taksta for Treatment of Prosthetic Joint Infections

Dec 14, 2012: Cempra Announces Initiation Of CEM-102 Phase II Clinical Trial In Patients With Prosthetic Joint Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Prosthetic Joint infections, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020

Prosthetic Joint infections - Pipeline by Arrevus Inc, H1 2020

Prosthetic Joint infections - Pipeline by ContraFect Corp, H1 2020

Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, H1 2020

Prosthetic Joint infections - Pipeline by Peptilogics Inc, H1 2020

Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, H1 2020

Prosthetic Joint infections - Pipeline by Telephus Medical LLC, H1 2020

Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, H1 2020

Prosthetic Joint infections - Dormant Projects, H1 2020

Prosthetic Joint infections - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Prosthetic Joint infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Armata Pharmaceuticals Inc

Arrevus Inc

ContraFect Corp

Lumobiotics GmbH

Peptilogics Inc

Sonoran Biosciences Inc

Telephus Medical LLC

TenNor Therapeutics Ltd

I would like to order

Product name: Prosthetic joint infections - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P498AF90CDAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P498AF90CDAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970